Deanna Marissa Schafer

Ms. Deanna Marissa Schafer


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
CPCayz Paclibar
Cayz Paclibar
DSDeanna Marissa Schafer
Deanna Marissa Schafer
ABAgnes Biju
Agnes Biju
FKFariha Karim
Fariha Karim
SSStephanie A. Sison
Stephanie A. Sison
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer’s disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A. Five molecules, 10-bromo-2-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (4E3), 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (KuFal184), harmine, 6-(fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (MK-6240), and 6-iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline (IPPI), were found to have binding energies of −10.4, −10.1, −9.0, −9.1, and −9.4 kcal/mole, respectively. Two molecules, 4E3 and KuFal184, were selective for DYRK1A, while harmine also had a monoamine oxidase A affinity, and MK-6240 and IPPI had affinity for Tau. Tau present in the brain slices of AD subject were labeled with [125I]IPPI. KuFal184 had no effect on the binding of [125I]IPPI, suggesting the absence of binding overlap of the two molecules. MK-6240, a known Tau agent was, however, able to compete with [125I]IPPI. The binding energies of harmine, MK-6240, and IPPI for the DYRK1A site suggest affinities of approximately 80–100 nM, which is insufficient to serve as an imaging agent. The higher affinity of KuFal184 (6 nM for DYRK1A) suggested that [125I]KuFal184 may be a potential imaging agent. Electrophilic radioiodination was used to synthesize [125I]KuFal184 in modest yields (25%) and high radiochemical purity (>95%). Preliminary binding studies with [125I]KuFal184 in AD brain slices showed some selectivity for cortical grey matter regions containing Tau.

21 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAgnes Biju
Agnes Biju
FKFariha Karim
Fariha Karim
DSDeanna Marissa Schafer
Deanna Marissa Schafer
SSStephanie A. Sison
Stephanie A. Sison
CLChristopher Liang
Christopher Liang
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
The accumulation of tau tangles and Aβ plaques are prominent neuropathologies that characterize Alzheimer’s disease (AD) and Down Syndrome (DS). Continuous developments of PET tracers as biomarkers can be supported by autoradiography to validate effectiveness and accuracy of binding properties that elucidate the pathophysiology of DSAD and AD. This in vitro comparative study evaluates [ 125 I]IPPI binding to tau and [ 125 I]IBETA binding to Aβ plaques in the frontal cortex (FCX) and temporal cortex (TCX) of postmortem human brain slices of AD (n=5), DSAD (n=5), and cognitively normal (CN) (n=5) cases. With anti-tau and anti-Aβ immunostains confirming the presence of tau and Aβ plaques, [ 125 I]IPPI and [ 125 I]IBETA binding in autoradiographic images were significantly higher in DSAD and AD gray matter (GM) compared to CN. When comparing DSAD with AD, FCX and TCX GM binding was similar throughout DSAD and AD except in FCX GM where there was 48% more [ 125 I]IPPI binding in DSAD than AD. In vitro drug inhibition studies revealed that [ 125 I]IPPI binding was significantly inhibited with increasing harmine concentrations (IC 50 =115±40 nM) in DSAD FCX and TCX but KuFal194 minimally inhibited [ 125 I]IPPI binding in the same cases. The GM/white matter ratios for DSAD ([ 125 I]IPPI=4.1, [ 125 I]IBETA=2.9) and AD ([ 125 I]IPPI=4.2, [ 125 I]IBETA=2.6) were significantly greater than CN ([ 125 I]IPPI=1.3, [ 125 I]IBETA=1.2). A positive correlation between [ 125 I]IPPI and [ 125 I]IBETA binding suggests a synergistic relationship between tau and Aβ plaque in DSAD and AD pathology. This study demonstrates that [ 125 I]IPPI and [ 125 I]IBETA may serve as novel radiotracers in both DSAD and AD to continue diagnostic investigations in vivo.